Astrazeneca Pharma India Ltd
Ticker: ASTRAZEN
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
9148.50
Market Cap
22871.25
Debt/Equity
0.0464
ROE %
15.617
PB
29.6894
Promoter %
75.000
Pledge %
0.000
1Y Rev Growth %
30.455
5Y Rev Growth %
15.771
NP Margin %
6.588
NP Margin 5Y Avg %
9.405
Trading Reference
1M Return %
1.311
6M Return %
3.099
1Y Return %
20.123
% Away 52W High
16.861
% Away 52W Low
47.082
Daily Volume
7740
Investment Verdict
Hold
Score 62/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 26/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Astrazeneca Pharma India Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If it breaks above the resistance level, there is a potential for upward movement; however, if it falls below the support, downside risk increases.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
C
Chalet Hotels Ltd
Chalet Hotels Ltd shows potential for growth in a recovering sector, but faces challenges in profitability and valuation metrics.
View details
M
Mangalore Refinery and Petrochemicals Ltd
Mangalore Refinery and Petrochemicals Ltd shows potential but faces several challenges that could impact future performance.
View details
K
Kalpataru Projects International Ltd
Kalpataru Projects International Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and execution risks.
View details
A
Aadhar Housing Finance Ltd
Aadhar Housing Finance Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
S
Sun Tv Network Ltd
Sun TV Network Ltd shows potential but faces significant challenges in growth and market adaptation.
View details
P
PNB Housing Finance Ltd
PNB Housing Finance Ltd shows potential in a growing sector but faces significant challenges in profitability and valuation metrics.
View details
C
Chambal Fertilisers and Chemicals Ltd
Chambal Fertilisers shows potential for growth but faces challenges in profitability and execution risks.
View details
S
Sundram Fasteners Ltd
Sundram Fasteners Ltd shows decent potential with moderate risks, but investors should be cautious about valuation and execution challenges.
View details
O
Onesource Specialty Pharma Ltd
Onesource Specialty Pharma Ltd shows potential in a growing sector, but faces challenges in execution and profitability. Caution is advised due to valuation concerns and market risks.
View details
C
CESC Ltd
CESC Ltd shows potential risks in growth and profitability, making it a risky investment at this time.
View details
P
PTC Industries Ltd
PTC Industries Ltd shows potential in a growing sector, but inconsistent financial performance and governance concerns pose significant risks.
View details
J
JSW Holdings Ltd
JSW Holdings Ltd shows potential for growth with a decent balance sheet and profitability metrics, but caution is advised due to some governance concerns and execution risks.
View details
S
Schneider Electric Infrastructure Ltd
Schneider Electric Infrastructure Ltd shows potential in a future-ready sector with decent growth prospects, but faces challenges in profitability and execution risks.
View details
E
eClerx Services Limited
eClerx Services Limited shows decent potential with consistent growth and a solid business model, but caution is advised due to some cash flow and governance concerns.
View details
S
Sagility Ltd
Sagility Ltd shows potential for growth, but investors should be cautious of execution risks and valuation metrics.
View details
S
Sarda Energy & Minerals Ltd
Sarda Energy & Minerals Ltd shows potential in a growing sector, but faces challenges in execution and profitability consistency.
View details
Business Overview
Astrazeneca Pharma India Ltd is a leading biopharmaceutical company dedicated to delivering innovative medicines that improve patient outcomes. Catering primarily to healthcare professionals and patients in India, the company focuses on areas such as oncology, cardiovascular, and respiratory diseases. Its commitment to research and development ensures that it remains at the forefront of medical advancements. By prioritizing patient needs and collaborating with healthcare providers, Astrazeneca plays a crucial role in enhancing healthcare standards across the nation.
- Leading biopharmaceutical company in India
- Focus on innovative medicines for critical health issues
- Strong commitment to research and development
- Collaborates with healthcare professionals
- Enhances healthcare standards across the nation
Investment Thesis
Astrazeneca Pharma India Ltd stands out due to its strong promoter credibility, which enhances investor confidence. The company is well-positioned to capitalize on the growing digital services market in healthcare. Additionally, its current valuation presents an attractive opportunity compared to peers, making it a compelling choice for investors seeking growth in the pharmaceutical sector.
- Strong backing from AstraZeneca PLC ensures robust governance and strategic direction.
- Significant growth potential in digital healthcare services aligns with market trends.
- Attractive valuation metrics compared to industry peers enhance investment appeal.
- Established product portfolio and pipeline support long-term growth prospects.
- Commitment to innovation positions the company for future market leadership.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Expanding market presence in India
- Potential for increased healthcare spending
- Strategic partnerships with local firms
Risks ⚠️
- Regulatory challenges in India
- Competition from generic drugs
- Pricing pressures from government policies
- Market volatility affecting stock performance
Peer Perspective
Astrazeneca Pharma India Ltd trades at a premium compared to peers like Sun Pharmaceutical and Cipla, driven by strong growth prospects. A sustained improvement in margins could trigger a rerating, aligning its valuation with industry leaders.
Future Outlook
AstraZeneca Pharma India Ltd is well-positioned for growth, driven by its robust pipeline and market expansion. Successful execution of its strategies and effective cost control will be crucial to maximize shareholder value.
AI FAQs for Retail Users
- Q: What does Astrazeneca Pharma India Ltd do?A: Astrazeneca Pharma India Ltd develops and manufactures pharmaceutical products, focusing on innovative medicines in various therapeutic areas.
- Q: Is Astrazeneca Pharma India Ltd a good investment?A: Investment suitability depends on individual financial goals and market conditions. Consider consulting a financial advisor.
- Q: What are the main products of Astrazeneca Pharma India Ltd?A: The company offers a range of medicines, including oncology, cardiovascular, and respiratory treatments.
- Q: How can I buy shares of Astrazeneca Pharma India Ltd?A: You can purchase shares through a stockbroker or an online trading platform.
- Q: What are the risks associated with investing in this stock?A: Risks include market volatility, regulatory changes, and company-specific factors that may affect performance.
📊 Stock Investment Checklist (100 Points)
Astrazeneca Pharma India Ltd • Updated: 2025-09-17 06:21:20
-
10BusinessHighPharmaceutical sector is essential and growing, but competition is intense.
-
10GrowthHighConsistent revenue growth observed, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are healthy, but OCF is fluctuating.
-
8ValuationHighP/E and P/B ratios are higher than industry averages.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
9GovernanceHighPromoter holding is strong, but some concerns over disclosures.
-
6DriversGoodGrowth drivers are present, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Astrazeneca Pharma India Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 80/100
- Governance: 65/100
- Market Confidence: 72/100